Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Faron Pharmaceuticals Capital Markets Day 2024

By Inderes
Faron Pharmaceuticals

The agenda is as follows:

  • Opening remarks
  • Faron's strategy and key focus areas - Dr. Juho Jalkanen, MD, PhD, CEO
  • BEXMAB clinical data - Dr. Mika Kontro, MD, PhD, principal investigator of the BEXMAB trial
  • BEXMAB MDS market assessment - Mr. Ralph Hughes, MSc, BSc
  • Faron's development plan for solid tumors - Dr. Petri Bono, MD, PhD, CMO
  • Who benefits from bexmarilimab and why - Future Addressable Markets - Dr. Maija Hollmén, PhD, CSO
  • Q&A session
  • Closing remarks

More information regarding Faron Pharmaceuticals CMD 2024

Stay up to date
CMD

Recent videos

Herantis Pharma Plc, Phase 1b biomarker data webcast
2026-01-08 11:00 Herantis Pharma
Investor Day | Nov. 24, 2025
2025-12-23 11:00 United Bankers
Uppesittarkväll 22/12 från Inderes Event Studio
2025-12-22 20:00
Talenom - Planned demerger and strategies of Talenom and Easor
2025-12-18 11:00 Talenom
Conference call with Fabege´s new CEO Bent Oustad
2025-12-18 10:00 Fabege
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.